← Eichor
Study identifier: NCT05810480 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

PredIcting sterOid depeNdEnt livEr injuRy With Polyreactive Immunoglobulin G

Condition: Autoimmune Hepatitis · Autoimmune Liver Disease  ·  Sponsor: Hannover Medical School

PhaseN/A
Planned participants400
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersYes

About this study

The investigators identified polyreactive immunoglobulin G (pIgG) in adults (published in Hepatology: https://doi.org/10.1002/hep.32134) and children (in preparation). Quantification of these pIgG using a "home-made" ELISA facilitates the diagnosis of autoimmune hepatitis (AIH) as compared to non-AIH liver diseases and healthy controls. Positivity for pIgG was independent from ANA/SMA positivity and equally diagnostic for AIH even when conventional autoantibodies (ANA/SMA/SLA/LKM) were negative. Additionally, the frequency of pIgG was lower than conventional autoantibodies (ANA, SMA) in vaccinia/drug associated severe liver injury in a retrospective multicenter study after Covid-19 vaccination (https://doi.org/10.1016/j.jhepr.2022.100605). Aims of the study The study aims to evaluate the diagnostic capacity of pIgG to predict AIH in comparison to other liver diseases prospectively. To avoid diagnostic inaccuracy between AIH with long-term need for an immunosuppression and drug induced liver injury with autoimmune features, which can be indistinguishable from AIH at baseline and which has a very low relapse rate after a short steroid course, a follow-up after six months is obligatory for inclusion. Therefore, the investigators will collect one serum sample from every patient (without immunosuppressive treatment) that presents to the respective hospital for evaluation of liver disease by liver biopsy within one year after initiation of the study and that provided written inf…

This description comes directly from the study's public registry record.

Talk to the study team

Bastian Engel, Dr.  ·  +49 511 532 6766  ·  Engel.Bastian@mh-hannover.de

Richard Taubert, Dr.  ·  +49 511 532 6766  ·  Taubert.Richard@mh-hannover.de

Always discuss trial participation with your own doctor first.

Locations (6)

RWTH AachenAachen, GermanyNot Yet Recruiting
University Medical Center Hamburg-EppendorfHamburg, GermanyNot Yet Recruiting
Hannover Medical SchoolHanover, GermanyRecruiting
University Medical Center HeidelbergHeidelberg, GermanyNot Yet Recruiting
University Hospital Schleswig-Holstein, Location LübeckLübeck, GermanyNot Yet Recruiting
Rostock University Medical CentreRostock, GermanyNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05810480